Compare Albertsons Companies Inc (ACI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs Sana Biotechnology Inc — how do they compare? Albertsons Companies Inc trades at $12.03 (market cap $5.95B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Albertsons Companies Inc is far larger — about 5.3× Sana Biotechnology Inc's market cap, and Albertsons Companies Inc pays a 5.55% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ACI | SANA | |
|---|---|---|
Market Cap | $5.95B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $5.92 |
52-Week Low | $11.03 | $2.68 |
Enterprise Value | $21.35B | $1.05B |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $11.98, down 1.24% with bearish technical signals despite recent insider buying by the CEO and CFO. The stock shows mixed fundamentals with strong revenue growth to $80.39B in 2025 but declining net margins to 0.08%. Recent Q2 2026 earnings missed expectations, triggering a 22% selloff and multiple legal investigations. Analyst consensus remains cautious with a $13.20 price target and 56.52% hold rating.
ACI presents a high-risk opportunity trading near multi-year lows with potential upside to analyst targets. Key catalysts include ACI Edge restructuring and digital initiatives, but investors face significant execution risks amid margin pressure and competitive grocery markets. The stock's deep value case is complicated by earnings volatility and ongoing legal scrutiny.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
